Wegovy Turns Up the Dial and Takes Aim at Lilly

The FDA approved Novo Nordisk's 7.2 mg Wegovy HD in 54 days, with trial data showing 20.7% average weight loss

26 Mar 2026

The obesity drug market has long resembled a two-horse race in which one horse keeps accelerating. Eli Lilly, whose tirzepatide-based therapies have captured more than 60% of the American market, has until recently enjoyed a clear efficacy edge over Novo Nordisk's semaglutide. That gap has now narrowed.

On March 19th, the FDA approved Wegovy HD, a 7.2 mg once-weekly semaglutide injection three times the strength of the version approved in 2021. The decision came in just 54 days, making it only the fourth drug cleared through the FDA's Commissioner's National Priority Voucher programme. Commissioner Martin Makary called the outcome a demonstration of "what the agency can accomplish" under its revised approach to obesity-drug reviews. Whether speed and rigour can reliably coexist remains a question worth asking.

The clinical case for approval was solid. In the phase 3 STEP UP trial, patients on Wegovy HD lost an average of 20.7% of their body weight over 72 weeks, compared with 17.5% on the standard dose. More striking, one-third of patients exceeded 25% weight loss, a threshold previously associated mainly with tirzepatide. Among patients with obesity and type 2 diabetes, the drug produced average weight loss of 14.1%. Side effects were broadly consistent with prior semaglutide experience, though a higher incidence of altered skin sensation was noted.

Novo Nordisk plans a US launch in April, through a single-dose injection pen distributed across more than 70,000 pharmacies and telehealth platforms. The product is already approved in the EU and UK. The timing is deliberate. After several quarters of ceding ground to Lilly, the company arrives with a formulation that gives clinicians a more powerful option for patients who have plateaued on standard doses.

The approval landed against a less flattering backdrop. On March 5th, the FDA issued a Warning Letter to Novo Nordisk over compliance failures in adverse event reporting for semaglutide. The company says remediation is underway and that production will not be disrupted. Investors will be watching both claims.

For the broader sector, the swifter review signals something structural: regulatory speed in obesity medicine is no longer an exception. More high-profile decisions are expected soon. The pipeline, like the waistline, keeps expanding.